Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy

Emily M. Hsieh; Regina M. Myers; Bonnie Yates; Colleen Annesley; Samuel John; Agne Taraseviciute; Seth M. Steinberg; Jennifer Sheppard; Perry Chung; Lee Chen; Daniel W. Lee; Amanda DiNofia; Stephan A. Grupp; Michael R. Verneris; Theodore W. Laetsch; Deepa Bhojwani; Patrick A. Brown; Michael A. Pulsipher; Susan R. Rheingold; Rebecca A. Gardner; Lia Gore; Nirali N. Shah; Adam J. Lamble

doi:10.1182/bloodadvances.2022008093

Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy

Emily M. Hsieh, Regina M. Myers, Bonnie Yates, Colleen Annesley, Samuel John, Agne Taraseviciute, Seth M. Steinberg, Jennifer Sheppard, Perry Chung, Lee Chen, Daniel W. Lee, Amanda DiNofia, Stephan A. Grupp, Michael R. Verneris, Theodore W. Laetsch, Deepa Bhojwani, Patrick A. Brown, Michael A. Pulsipher, Susan R. Rheingold, Rebecca A. GardnerLia Gore, Nirali N. Shah, Adam J. Lamble

Research output: Contribution to journal › Letter › peer-review

9 Scopus citations

Original language	English (US)
Pages (from-to)	5222-5226
Number of pages	5
Journal	Blood Advances
Volume	6
Issue number	17
DOIs	https://doi.org/10.1182/bloodadvances.2022008093
State	Published - Sep 13 2022
Externally published	Yes

ASJC Scopus subject areas

Hematology

Access to Document

10.1182/bloodadvances.2022008093

Cite this

Hsieh, E. M., Myers, R. M., Yates, B., Annesley, C., John, S., Taraseviciute, A., Steinberg, S. M., Sheppard, J., Chung, P., Chen, L., Lee, D. W., DiNofia, A., Grupp, S. A., Verneris, M. R., Laetsch, T. W., Bhojwani, D., Brown, P. A., Pulsipher, M. A., Rheingold, S. R., ... Lamble, A. J. (2022). Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy. Blood Advances, 6(17), 5222-5226. https://doi.org/10.1182/bloodadvances.2022008093

Hsieh, EM, Myers, RM, Yates, B, Annesley, C, John, S, Taraseviciute, A, Steinberg, SM, Sheppard, J, Chung, P, Chen, L, Lee, DW, DiNofia, A, Grupp, SA, Verneris, MR, Laetsch, TW, Bhojwani, D, Brown, PA, Pulsipher, MA, Rheingold, SR, Gardner, RA, Gore, L, Shah, NN & Lamble, AJ 2022, 'Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy', Blood Advances, vol. 6, no. 17, pp. 5222-5226. https://doi.org/10.1182/bloodadvances.2022008093

@article{a525cf8dc1b9464fbc8b5973b2101a44,

title = "Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy",

author = "Hsieh, {Emily M.} and Myers, {Regina M.} and Bonnie Yates and Colleen Annesley and Samuel John and Agne Taraseviciute and Steinberg, {Seth M.} and Jennifer Sheppard and Perry Chung and Lee Chen and Lee, {Daniel W.} and Amanda DiNofia and Grupp, {Stephan A.} and Verneris, {Michael R.} and Laetsch, {Theodore W.} and Deepa Bhojwani and Brown, {Patrick A.} and Pulsipher, {Michael A.} and Rheingold, {Susan R.} and Gardner, {Rebecca A.} and Lia Gore and Shah, {Nirali N.} and Lamble, {Adam J.}",

note = "Funding Information: poon Therapeutics, has advised for Amgen and Bristol Myers Squibb, and has received research funding from Kite Pharma and Gilead. S.A.G. has received research funding from Novartis, Kite Funding Information: This work was supported in part by the Center for Cancer Research and the Warren Grant Magnuson Clinical Center, Intramural Research Program, National Cancer Institute, National Institutes of Health (grant ZIA BC 011823; N.N.S.). L.G. is supported by grant CA046934.",

year = "2022",

month = sep,

day = "13",

doi = "10.1182/bloodadvances.2022008093",

language = "English (US)",

volume = "6",

pages = "5222--5226",

journal = "Blood Advances",

issn = "2473-9529",

publisher = "American Society of Hematology",

number = "17",

}

TY - JOUR

T1 - Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy

AU - Hsieh, Emily M.

AU - Myers, Regina M.

AU - Yates, Bonnie

AU - Annesley, Colleen

AU - John, Samuel

AU - Taraseviciute, Agne

AU - Steinberg, Seth M.

AU - Sheppard, Jennifer

AU - Chung, Perry

AU - Chen, Lee

AU - Lee, Daniel W.

AU - DiNofia, Amanda

AU - Grupp, Stephan A.

AU - Verneris, Michael R.

AU - Laetsch, Theodore W.

AU - Bhojwani, Deepa

AU - Brown, Patrick A.

AU - Pulsipher, Michael A.

AU - Rheingold, Susan R.

AU - Gardner, Rebecca A.

AU - Gore, Lia

AU - Shah, Nirali N.

AU - Lamble, Adam J.

N1 - Funding Information: poon Therapeutics, has advised for Amgen and Bristol Myers Squibb, and has received research funding from Kite Pharma and Gilead. S.A.G. has received research funding from Novartis, Kite Funding Information: This work was supported in part by the Center for Cancer Research and the Warren Grant Magnuson Clinical Center, Intramural Research Program, National Cancer Institute, National Institutes of Health (grant ZIA BC 011823; N.N.S.). L.G. is supported by grant CA046934.

PY - 2022/9/13

Y1 - 2022/9/13

UR - http://www.scopus.com/inward/record.url?scp=85138098811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85138098811&partnerID=8YFLogxK

U2 - 10.1182/bloodadvances.2022008093

DO - 10.1182/bloodadvances.2022008093

M3 - Letter

C2 - 35834728

AN - SCOPUS:85138098811

SN - 2473-9529

VL - 6

SP - 5222

EP - 5226

JO - Blood Advances

JF - Blood Advances

IS - 17

ER -

Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this